Skip to main content
. 2019 Nov 7;15(11):e1008061. doi: 10.1371/journal.ppat.1008061

Fig 6. In vivo properties of human mAbs in mice.

Fig 6

(A) Protective efficacy using a prophylactic dosing regime (day -1) against CHIKV LR2006_OPY1 in 3-week old mice rendered immunodeficient with anti-Ifnar1 mAb. Survival curves were compared using the log-rank test with a Bonferroni correction. Results were combined from two independent experiments of five mice per treatment group (n = 10). (B) Serum mAb levels 48 hours after mAb administration in infected mice from (A) (“I”, closed symbols) and 60 hours after mAb administration in uninfected mice (“U”, open symbols). There were three mice per group points represent mean ± SD). Serum mAb levels were compared by unpaired t-test. (C) Therapeutic dosing regimen, similar to (A) but CHIKV mAbs were administered at day +1. Analysis as in (A).